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Poster Session II S299p5 0.035) and higher overall survival (HR: 0.60, 95%CI: 0.36-0.99,
p5 0.047) than those who received stem cells from a donor without
the C-A-A haplotype. Additionally, the group with the
C-A-A haplotype exhibited high disease-free survival (HR: 0.66,
95%CI: 0.41-1.06, p5 0.085), compared with the group without
the haplotype C-A-A. The presence or absence of the C-A-A haplo-
type did not affect the incidence of acute and chronic GVHD, and
non-relapse mortality. This is the first report described the effect
of CTLA-4 haplotype, but not each SNP, on allogeneic HSCT.
Since the presence of CTLA-4 haplotype C-A-A reduced the risk
of relapse and improved survival after allogeneic HSCT, CTLA-4
haplotype may provide useful information for donor selection.Blockade of two independent innate immunity pathways syn-
ergistically prevent lethal graft-versus-host disease
Groups n
Survival at
day 150
Survival at
day 1100
TCD BM alone 10 100% 100%
Wildtype 1 isotype 10 20% 10%
Wildtype 1 anti-C5 10 40% 30%
MyD88-/- 1 isotype 10 50% 20%
MyD88-/- 1 anti-C5 10 90% 80%
P\0.01, MyD88-/-1 anti-C5 vs. other groups. A representative exper-
iment of three is shown.383
EPIGENETICCONTROLOFGVHDANDGVLUSINGTHEHYPOMETHYLATING
AGENT AZACITIDINE
Choi, J., Ritchey, J., DiPersio, J.F. Washington University School of
Medicine, St. Louis, MO
Allogeneic bone marrow transplantation (BMT) represents the
most effective treatment for patients with high risk and relapsed
hematologic malignancies because allogeneic donor T cells pro-
vide a graft-versus-leukemia (GvL) effect. However, the same cells
can cause graft-versus-host disease (GvHD), one of the major
complications. Regulatory T cells (Tregs) have been shown to
suppress GvHD while preserving GvL, their use provides a prom-
ising strategy in the allogeneic transplant setting if three major
obstacles will be overcome: 1) the low numbers of Tregs, 2)
loss of suppressor activity following ex vivo expansion and 3) the
lack of Treg-specific markers to purify ex vivo expanded Tregs.
The FOXP3 transcription factor, which is exclusively expressed
in Tregs, can convert effector T cells (Teff) into Tregs when ec-
topically overexpressed. The Foxp3 locus is unmethylated in Tregs
while highly methylated and silenced in all other T cells. The hy-
pomethylating agent azacitidine (AzaC) can modulate this methyl-
ation status and induce stable FOXP3 expression (.7 days) in
Teff. Furthermore, we have shown that these AzaC-induced
FOXP3 +T cells are suppressive phenotype in vitro. Thus, we hy-
pothesize that AzaC treatment of mice after allogeneic BMT will
dramatically mitigate GvHD while preserving GvL via upregula-
tion of Foxp3 in alloreactive Teff.
In murine T cell depleted (TCD) BMT model (B6/ Balb/c)
with delayed infusion of conventional T cells (Tconv) (2X106) at
day 11 post BMT, followed by subcutaneous treatment of AzaC
(2 mg/kg at days 15, 17, 19, and 21 post BMT), we found that
AzaC dramatically suppressed GvHD caused by allogeneic donor
T cells while maintaining donor engraftment of all lineages. The
AzaC group had significantly higher FOXP3 +Tregs than in PBS
control group and that these Tregs were derived from donor T
cells, suggesting that the suppression of GvHD was mediated by
AzaC-induced Tregs. We further tested whether AzaC treatment
of mice transplanted with allogeneic T cells preserve GvL while
mitigating GvHD. Using the same murine allogeneic BMT
model, Click Beetle Red luciferase-expressing A20 leukemia cells
(Balb/c derived; 1X104) were injected with TCD BM and
10106 Tconv and in vivo bioluminescence imaging was per-
formed to assess tumor burden. We found that AzaC treatment
mitigated GvHD without abrogating GvL or donor engraftment.
Thus, the adminstration of hypomethylating agents like AzaC
might be a promising strategy to treat GvHD.384
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Graft-versus-host disease (GVHD) is a major complication fol-
lowing hematopoietic cell transplantation. Innate immunity plays
a major role in the development of GVHD both by aiding allogeneic
T cell responses and by damaging target organs directly. MyD88 is
an adaptor protein for the majority of toll-like receptors. The com-plement system is a central component of the innate immune
response. We studied the role of these two pathways in the develop-
ment of GVHD using the C57BL/6 into BALB/c model. Lethally
irradiated recipients of MyD88-/- T cells survived slightly longer
than recipients of wild type cells (median survival time: 48 vs. 32
days, P\0.05). Similarly, treatment with an anti-C5 antibody (clone
BB5.1, 1 mg/dose, i.p., three times a week for 4 weeks), that blocks all
three pathways of complement activation and prevents cell lysis, also
moderately prolonged the survival of the mice with GVHD com-
pared with the isotype control group (median survival time: 43 vs.
32 days). Treatment of MyD88-/- T cell recipients with anti-C5 an-
tibody protected 80% of the animals from lethal GVHD at 100 days
post transplantation, while only 20% in the MyD88-/- T cell recipi-
ents treated with isotype antibody group and 30% in the wildtype T
cell recipients treated with anti-C5 antibody group survived (Table,
P\0.01, compared with other groups). All MyD88-/- T cell recipi-
ents treated with anti-C5 antibody developed GVHD.However, the
disease was less severe in these animals than those in the recipients of
a single pathway blockade as measured by body weight and other
clinical signs of GVHD. The anti-C5 antibody did not seem to pre-
vent GVHD through inhibiting T cell activation and expansion
because it did not inhibit mixed lymphocyte reactions. Levels of mul-
tiple pro-inflammatory cytokines were lower in the MyD88-/- T cell
recipients treated with anti-C5 antibody compared with those in the
control groups. These data clearly demonstrate that, even though
blockade of MyD88 or complement pathway alone may prevent
GVHD, GVHD can be better controlled by blocking both
MyD88 and complement pathways.385
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Mycophenolate mofetil (MMF) is a common and effective pro-
phylactic immune suppressant that promotes hematopoietic cell en-
graftment and prevents graft vs host disease (GVHD) after
allogeneic hematopoietic stem cell transplant (HCT). However,
there is limited data as to the effectiveness of MMF plus high dose
corticosteroids for the treatment of acute GVHD and even less
data regarding the pharmacokinetic disposition and exposure-re-
sponse relationship of mycophenolate in individuals with GVHD.
Mycophenolate pharmacokinetics were studied in a multi-center
CTN randomized phase II trial evaluating the effectiveness of
MMFas one if four novel agents added to steroids as initial treatment
of acute GVHD. Thirty-two patients randomized to receiveMMF 1
gm twice daily who underwent pharmacokinetic sampling in weeks 1
and 2 were studied. Median age was 416 13.6 years. Twenty one
(65.6%), 5 (15.6%), 6 (18.8%) patients had a complete response
(CR), partial response (PR) or lesser response by day 28, respectively.
S300 Poster Session IITwenty-five (78.1%), 2 (6.3%), 5 (15.6%) patients had a CR, PR, or
other response by day 56 to treatment, respectively. Singlemycophe-
nolic acid (MPA) pharmacokinetic measurements during weeks 1
and 2 did not correlate with CR at either day 28 or 56 (p. 0.07).
However, if the mean of weeks 1 and 2 total MPA troughs was
.0.5 mcg/mL or unbound trough .0.015 mcg/mL, a significantly
greater proportion achieved a CR + PR at day 28 and 56. A
CR + PR at day 28 was observed in 19/19 (100%) of patients if the
mean total trough was .0.5 mg/mL, but in only 7/13 (54%) if
#0.5 mcg/mL (p5 0.002). Similarly, 15/15 (100%) individuals
had a CR + PR at day 28 if their unboundMPA trough concentration
was .0.015 mcg/mL while only 11/17 (65%) responded if trough
was #0.015 mcg/mL (p5 0.02). There was no association with
risk of infection by day 90, overall survival at day 180 post random-
ization and any pharmacokinetic measures. About one-half of sub-
jects’ therapy did not achieve the favorable MPA total and
unbound trough targets. The current practice of MMF 1 gm twice
daily dosing provides low plasma concentrations in many patients.
Increased dosing at 3 gm/day may improve the efficacy of MMF as
acute GVHD therapy.386
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In fully HLA matched, allogeneic hematopoietic cell transplan-
tation (HCT), minor histocompatibility antigens (miHAs) recog-
nized by donor cytotoxic T cells are believed to be the main
cause of graft versus host (GVH) disease and the graft-versus-tu-
mor (GVT) effect. Differences in non-synonymous coding single
nucleotide polymorphisms (nsSNPs) between donor and patient
are the most common cause of miHAs. Approximately 30 mi-
HAs, mostly pertaining to HLA-A*0201, have been identified
so far, but considering the numerous different HLA-types in
the human population and possible nsSNP differences between
any two individuals it seems likely that many miHAs have yet
to be identified. The objective of the current study was to predict
the number of possible miHAs in 11 proteins using an in silico
approach and assess the influence of the number of predicted mi-
HAs on outcome after allogeneic HCT following non-myeloabla-
tive conditioning (NMC). miHA predictions were performed
using the publicly available network based tool, netMHCpan,
which can predict the binding of peptides to more than 1000 dif-
ferent HLA-A and B molecules. The study cohort consisted of
126 patients treated with allogeneic HCT following NMC
(matched related donor, n5 70; matched unrelated donors,
n5 56) for hematologic malignancies, and was genotyped for
53 nsSNPs, in 11 proteins known to contain miHAs. For each
patient/donor pair, a predicted miHA in the GVH direction,
was defined as a peptide with a nsSNP-variant unique to the
patient and with a predicted binding to any of the HLA-A or
–B molecules expressed by the patient and donor. Twenty-three
nsSNPs within 6 proteins showed variation in the GVH-direc-
tion. Patients with more than 5 predicted miHAs had a signifi-
cantly lower overall survival (40% vs 73%, p5 0.002, hazard
ratio (HR) 2.6, p5 0.003) and treatment related mortality
(38% vs 11%, p5 0.019, HR 3.2, p5 0.016) than patients with
5 or fewer predicted miHAs. No association between number
of miHAs and any other clinical outcome parameter was
observed. Collectively, our data suggest that six of the 11 pro-
teins included in the current study could contain more miHAs,
that have yet to be identified, and that the presence of multiple
miHAs confers a higher risk of mortality after NMC condition-
ing HCT. Furthermore, our data suggest a possible role for in
silico based miHA prediction, in both donor selection and in
selecting candidate miHAs for further evaluation in in vitro and
in vivo experiments.387
PR1-SPECIFIC T CELL RESPONSES IN THE FIRST MONTHS FOLLOWING
T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION OCCUR
IN BOTH MYELOID AND NON-MYELOID MALIGNANCIES BUT ARE ONLY
ASSOCIATED WITH A GVL EFFECT IN MYELOID LEUKEMIAS
Rezvani, K.1,2, Mielke, S.1,3, Yong, A.1, Savani, B.N.1,4, Jafarpour, B.1,
Eniafe, R.1, Barrett, A.J.1 1National Institutes of Health; 2 Imperial Col-
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Lymphopenia-driven homeostasis post-SCT allows expansions of
donor T-cells against antigens (Ag). Leukemia-associated-Ag pro-
teinase 3 (PR3) & elastase (ELA2) are self-Ag which induce low
frequency autoreactive T-cells in normal controls. PR1, an HLA-
A*0201 epitope shared by PR3 & ELA2, is expressed in normal
neutrophils & overexpressed in myeloid (not lymphoid) leukemias.
T-cells against PR1 have been linked to GVL. We looked for
PR1-CD8 +T-cells in 28 patients (13CML, 10 ALL, 5 solid tumors)
at day +30-120 following T-cell depleted SCT, using PR1/HLA-A2
tetramers & IC-IFN-g staining & correlated them with ELA2 &
PR3 expression (using qRT-PCR) & GVL. Ten CML, 6 ALL & 3
solid tumor patients had PR1 responses post-SCT. PR3&ELA2 ex-
pressionwas strongly associated with emergence of PR1-T-cells. Re-
duction in PR3&ELA-2 expression coincided with disappearance of
PR1-T-cells (P\0.001). In-vivo anti-leukemia effect of the PR1 re-
sponse was assessed in CML patients by BCR-ABL qRT-PCR: 9/10
patients with early PR1 responses were BCR-ABL negative at day
+90 compared to 0/3 without (P\0.001).This GVL association
was restricted to CML: in ALL, using WT1 qRT-PCR to measure
MRD, 2/5 patients with PR1 responses & 3/5 patients without
were MRD+ on day 90 (P5 0.36). Since PR1 responses were not
CML restricted and all patients had 100% donormyeloid chimerism
by day 30, the recovering myeloid hematopoiesis from the donor is
the likely antigenic source of PR3&ELA2 driving the PR1 response.
Based on this hypothesis we initiated a clinical trial in patients with
relapsed AML to receive weekly vaccination with theWT1-126 pep-
tide admixed with Montanide adjuvant plus GM-CSF following an
immunotherapy approach of lymphodepletion by Fludarabine & in-
fusion of autologous lymphocytes collected prior to chemotherapy.
All 3 patients enrolled so far had detectableWT1-CD8 +T cells fol-
lowing vaccination. Interestingly, PR1-CD8 +T-cells were also
detected in 3/3 evaluable patients during hematopoietic recovery, as-
sociated with increases in PR3 & ELA2 expression. These data sug-
gest the induction of an ‘auto-vaccination’ process by the recovering
marrow & that the lymphopenic milieu permits exaggerated weak
autoimmune responses to normal self-Ag such as PR1. This immune
response may result in GVL if the self-antigen is also expressed on
the leukemia as in CML. Vaccination together with induction of
T-cell homeostatic proliferation is likely to enhance the anti-leuke-
mia response of SCT.388
CCR5+ T CELLS MEDIATE ALLOIMMUNE RESPONSES IN HUMAN GRAFT
VERSUS HOST DISEASE
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Gooley, T.A.2, Sale, G.E.2, Storb, R.F.2 1UTM.D.Anderson Cancer Cen-
ter, Houston, TX; 2Fred Hutchinson Cancer Research Center, Seattle,WA
Graft-versus-host disease (GVHD), a common complication that
is caused by donor T cells following allogeneic hematopoietic cell
transplant (HCT). The function of CCR5 in GVHD has been pri-
marily explored in murine models and the data suggested a compli-
cated role of CCR5 in alloimmmune responses. We have identified
unrelated MHC-matched HCT donors genetically lacking CCR5
(CCR5d32) and correlated presence or absence of CCR5 with
HCT outcomes. Patients were 18-50 years old, and they received cy-
clophosphamide and fractionated total body irradiation, unmanipu-
lated marrow, and GVHD prophylaxis with cyclosporine and
methotrexate. A total of 344 CML patients had CCR5 wild-type do-
nors, 39 had CCR5d32 heterozygous donors, and 8 had CCR5d32
homozygous donors. Logistic regression model was used to assess
the association between CCR5 genotype and acute GVHD, and
Cox regression was used for chronic GVHD. Results in the Table
suggested a trend of less GVHD among patients whose donors
were CCR5d32 homozygous compared to patients with wild-type
or heterozygous donors.
